Literature DB >> 12500017

Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability.

Luc M Hondeghem1, Peter Hoffmann.   

Abstract

Drug-induced proarrhythmia is a rare but potentially lethal adverse drug reaction. To test whether the SCREENIT system (an automated computerized test apparatus), using an isolated perfused heart obtained from female rabbits, could correctly identify agents that lengthen the action potential duration (APD) and drugs known to induce proarrhythmia, 14 drugs (penicillin G, haloperidol, adriamycin, indapamide, verapamil, aspirin, lidocaine, clomipramine, propranolol, erythromycin, quinidine, terfenadine, amiodarone, and thioridazine) were coded and submitted for a blinded test. Of these drugs, eight are reported to induce QT prolongation in the clinic (adriamycin, clomipramine, quinidine, amiodarone, and thioridazine), while three do not lengthen and three shorten the QT. To test for reproducibility, four drugs were given in duplicate (haloperidol, aspirin, erythromycin, and terfenadine). The drug effects on monophasic APD, conduction, instability (index of variability of APD), triangulation (index of duration of fast repolarization), and reverse use dependence were measured at five drug concentrations (0.05, 0.15, 0.5, 1.5, and 5 mg/l). All 14 blinded drugs, in the concentrations used, were correctly identified as to their effects on APD and conduction. The drugs eliciting drug-induced proarrhythmia in patients were also identified as promoting instability, triangulation, and reverse use dependence in the rabbit heart. Importantly, none of the safe agents was labeled as proarrhythmic, and the results were very consistent between duplications. In conclusion, SCREENIT correctly identifies prolongation of APD, accurately separates safe agents form proarrhythmic drugs, and has highly reproducible results. Thus, the isolated perfused rabbit heart can be a valuable tool in a preclinical proarrhythmia test battery in drug development.

Entities:  

Mesh:

Year:  2003        PMID: 12500017     DOI: 10.1097/00005344-200301000-00003

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  26 in total

Review 1.  Drug-induced long QT syndrome.

Authors:  Prince Kannankeril; Dan M Roden; Dawood Darbar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias.

Authors:  Tengxian Liu; Barry S Brown; Ying Wu; Charles Antzelevitch; Peter R Kowey; Gan-Xin Yan
Journal:  Heart Rhythm       Date:  2006-04-22       Impact factor: 6.343

3.  A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes.

Authors:  C L Lawrence; M H Bridgland-Taylor; C E Pollard; T G Hammond; J-P Valentin
Journal:  Br J Pharmacol       Date:  2006-10-09       Impact factor: 8.739

Review 4.  Clinical and genetic determinants of torsade de pointes risk.

Authors:  Andrew J Sauer; Christopher Newton-Cheh
Journal:  Circulation       Date:  2012-04-03       Impact factor: 29.690

Review 5.  Evolution of strategies to improve preclinical cardiac safety testing.

Authors:  Gary Gintant; Philip T Sager; Norman Stockbridge
Journal:  Nat Rev Drug Discov       Date:  2016-02-19       Impact factor: 84.694

6.  Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres.

Authors:  Pascal Champeroux; Karen Viaud; Abdel Ilah El Amrani; John Sinclair Lawrence Fowler; Eric Martel; Jean-Yves Le Guennec; Serge Richard
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

Review 7.  QT interval abnormalities: risk factors and perioperative management in long QT syndromes and Torsades de Pointes.

Authors:  Alan David Kaye; Jacqueline Volpi-Abadie; J Michael Bensler; Adam M Kaye; James H Diaz
Journal:  J Anesth       Date:  2013-02-15       Impact factor: 2.078

8.  Arrhythmogenic consequences of myofibroblast-myocyte coupling.

Authors:  Thao P Nguyen; Yuanfang Xie; Alan Garfinkel; Zhilin Qu; James N Weiss
Journal:  Cardiovasc Res       Date:  2011-11-02       Impact factor: 10.787

9.  Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin.

Authors:  Daniel Scherer; Katharina von Löwenstern; Edgar Zitron; Eberhard P Scholz; Ramona Bloehs; Sven Kathöfer; Dierk Thomas; Alexander Bauer; Hugo A Katus; Christoph A Karle; Claudia Kiesecker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-05-06       Impact factor: 3.000

10.  Drug-Induced QT Prolongation and Torsades de Pointes: An All-Exclusive Relationship or Time for an Amicable Separation?

Authors:  Luc M Hondeghem
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.